Devonian Health Group Inc has revealed a potential expanded therapeutic application for Thykamine, with compelling preclinical data results demonstrating proof of concept efficacy in a well-established animal model of pulmonary fibrosis.
The study investigated the effects of Thykamine in a bleomycin-induced pulmonary fibrosis (IPF) mouse model, a widely used preclinical tool for studying idiopathic pulmonary fibrosis pathophysiology and testing antifibrotic therapies. Pulmonary fibrosis was induced in mice using intranasal bleomycin, a gold-standard and clinically relevant model that closely mirrors key pathological features of human IPF.
Key Takeaways:
- Demonstrated Antifibrotic Efficacy: Thykamine showed statistically significant reductions in lung fibrosis, inflammation, and collagen-related gene expression in the bleomycin-induced model.
- Dose-Responsive, Low-Dose Activity: At doses as low as 0.5 mg/kg, Thykamine improved lung pathology and molecular markers, outperforming pirfenidone in key physiological endpoints within the study.
- Expanded Therapeutic Potential: These findings position Thykamine as a promising disease-modifying candidate for pulmonary fibrosis and other fibro-inflammatory conditions, addressing a major unmet medical need.
In this model, Thykamine demonstrated statistically significant antifibrotic activity, while pirfenidone did not reach statistical significance in physiological endpoints. Treatment with Thykamine at 0.5 mg/kg significantly reduced lung wet weight and lung tissue index compared with the bleomycin/vehicle group.
Bleomycin exposure led to marked increases in fibrosis (Ashcroft score) and inflammation compared with sham controls. Thykamine treatment significantly reversed these pathological changes, reducing both fibrosis and inflammation scores and indicating meaningful improvement in lung morphology.
This well-validated model delivers a strong, dose-responsive demonstration of efficacy across multiple translational endpoints, clearly positioning Thykamine as a differentiated, next-generation therapeutic candidate in pulmonary fibrosis. The Company plans to present data in an upcoming scientific publication.
About Thykamine™
Thykamine is a novel, plant-derived pharmaceutical ingredient extracted from spinach thylakoid membranes, developed by Devonian Health Group for inflammatory and autoimmune conditions. It acts as a potent antioxidant and anti-inflammatory agent, showing promise in treating mild-to-moderate atopic dermatitis, ulcerative colitis, and pulmonary fibrosis.
